Felzartamab

Phase 3Monoclonal antibody

Biogen

Felzartamab is one of 57 small molecule programs targeting Antibody-mediated Rejection. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Antibody-Mediated RejectionEnrolling by invitation

Primary Membranous NephropathyRecruiting

Kidney TransplantRecruiting

Graves DiseaseRecruiting

Antibody-Mediated RejectionPhase 3

Enrolling by invitation

Primary Membranous NephropathyPhase 3

Recruiting

Kidney TransplantPhase 3

Recruiting

Graves DiseasePhase 2

Recruiting

Competition

Competitive Landscape

121 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Ultomiris

AstraZeneca

Phase 3

1 2

Prevymis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

3 3

Biological/vaccine

Vertex Pharmaceuticals

Phase 3

1 4

Felzartamab

Biogen

Phase 3

1 5

Envarsus XR

UUniversity of Wisconsin, Madison

Phase 3

2 6

Cytogam

JJohns Hopkins University

Phase 3

2 7

Zemplar

AbbVie

Preclinical

2 8

Radicava

Shionogi

Preclinical

1 9

Cysteine Hydrochloride

Novartis

Preclinical

1 10

Sensipar

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Kidney Transplant

NCT06685757

Q1 2028

Phase 2Recruiting

Microvascular Inflammation

NCT07219043

Phase 2Recruiting

Graves Disease

NCT07722546

Q2 2029

Phase 3Recruiting

Immunoglobulin a Nephropathy (igan)

NCT06935357

Q1 2031

Phase 3Recruiting

Primary Membranous Nephropathy

NCT06962800

Clinical

Trials by Indication[1]

Antibody-mediated Rejection2 trials

Felzartamab in Late Antibody-Mediated Rejection

Completed·FFarsad Eskandary·Phase 2·NCT05021484·22 enrolled

An Open-Label Long-Term Extension Study of Felzartamab in Participants With Antibody-Mediated Rejection or Microvascular Inflammation Previously Enrolled in TRANSCEND or TRANSPIRE

Enrolling by invitation· Biogen logo

Biogen·Phase 3·NCT07444489·201 enrolled

IgA Nephropathy1 trial

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

Completed·HHI-Bio, A Biogen Company·Phase 2·NCT05065970·54 enrolled

Kidney Transplant1 trial

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

Recruiting· Biogen logo

Biogen·Phase 3·NCT06685757·120 enrolled

Microvascular Inflammation1 trial

A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants With Late Isolated Microvascular Inflammation (MVI)

Recruiting· Biogen logo

Biogen·Phase 2·NCT07219043·81 enrolled

Immunoglobulin A Nephropathy (IgAN)1 trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL)

Recruiting· Biogen logo

Biogen·Phase 3·NCT06935357·454 enrolled

3 more indications

Graves disease1 trial

A Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab Compared to Placebo in Adult Participants With Graves' Disease

Recruiting· Biogen logo

Biogen·Phase 2·NCT07722546·60 enrolled

Primary Membranous Nephropathy1 trial

An Open-Label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants With Primary Membranous Nephropathy (PMN) [PROMINENT]

Recruiting· Biogen logo

Biogen·Phase 3·NCT06962800·180 enrolled

Lupus Nephritis1 trial

An Open Label Phase 1b Study of Felzartamab in Lupus Nephritis

Completed·HHI-Bio, A Biogen Company·Phase 1·NCT06064929·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Felzartamab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Felzartamab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Felzartamab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biogen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Biogen

Felzartamab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2028

Q2 2029

Q1 2031

Trials by Indication[1]

Antibody-mediated Rejection2 trials

IgA Nephropathy1 trial

Kidney Transplant1 trial

Microvascular Inflammation1 trial

Immunoglobulin A Nephropathy (IgAN)1 trial

Graves disease1 trial

Primary Membranous Nephropathy1 trial

Lupus Nephritis1 trial

References

Drug Info

Quick Facts

Related News